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Aims Anthracyclines increase heart failure (HF) risk, but the long-term prevalence of myocardial dysfunction in young
breast cancer (BC) survivors is unknown. Early measures of left ventricular myocardial dysfunction are needed to
identify BC patients at risk of symptomatic HF.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
Within an established cohort, we studied markers for myocardial dysfunction among 569 women, who were 5–7 years
(n = 277) or 10–12 years (n = 292) after BC treatment at ages 40–50 years. Left ventricular ejection fraction (LVEF)
and global longitudinal strain (GLS) were assessed by echocardiography. N-terminal pro-brain natriuretic peptide
(NT-proBNP) was measured in serum. Associations between patient-related and treatment-related risk factors
and myocardial dysfunction were evaluated using linear and logistic regression. Median ages at BC diagnosis and
cardiac assessment were 46.7 and 55.5 years, respectively. Anthracycline-treated patients (n = 313), compared to
the no-anthracycline group (n = 256), more often had decreased LVEF (10% vs. 4%), impaired GLS (34% vs. 27%) and
elevated NT-proBNP (23% vs. 8%). GLS and LVEF declined in a linear fashion with increasing cumulative anthracycline
dose (GLS: +0.23 and LVEF: −0.40 per cycle of 60mg/m2; P< 0.001) and GLS was worse for patients with left breast
irradiation. The risk of NT-proBNP >125 ng/L was highest for patients who received 241–300mg/m2 anthracycline
dose compared to the no-anthracycline group (odds ratio: 3.30, 95% confidence interval: 1.83–5.96).
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Conclusion Impaired GLS and increased NT-proBNP levels are present in a substantial proportion of young BC survivors treated
with anthracyclines. Whether this will lead to future cardiac disease needs to be evaluated by longitudinal assessment.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
Anthracyclines have been the cornerstone of chemotherapy reg-
imens for early breast cancer (BC) since the 1990s.1 They are
known, however, for their cardiotoxicity that can affect BC sur-
vivors’ quality of life and life expectancy.2 Despite awareness of
*Corresponding author. Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Tel: +31 20 512 2483, Fax: +31 20 512 2322, Email: f.v.leeuwen@nki.nl
†The first two authors contributed equally to the study.









. anthracycline-related cardiotoxicity, no evidence-based guidelines
to monitor cardiac function of long-term BC survivors are cur-
rently available.3–5 In order to develop such guidelines it is of
paramount importance to better identify survivors at high risk
of developing cardiotoxicity and to evaluate methods for early
detection.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and
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Many studies have investigated the incidence of
anthracycline-related cardiotoxicity by echocardiographic mea-
surement of left ventricular ejection fraction (LVEF) as an indicator
of systolic (dys)function.6–8 Incidence rates of systolic dysfunction
range from 1–12% and are difficult to compare across studies
due to lack of a uniform definition for cardiotoxicity and substan-
tial differences in study populations in terms of age, follow-up
time and prevalence of co-morbid conditions. Moreover, studies
reporting on myocardial dysfunction beyond 10 years of follow-up
are scarce.9,10
Since LVEF decline can occur as a late manifestation of cardiac
injury, earlier and more sensitive markers that identify myocardial
dysfunction may be valuable. A promising technique to identify left
ventricular (LV) dysfunction is myocardial deformation imaging11;
measurement of global longitudinal strain (GLS) can detect changes
in contractility before LVEF decreases.12 Additionally, serial mea-
surements of cardiac biomarkers such as N-terminal pro-brain
natriuretic peptide (NT-proBNP) – an established screening tool
for heart failure in the general population13 – may be useful to
detect myocardial dysfunction in BC survivors.14–17
Little is known about the long-term prevalence of myocardial
dysfunction in BC survivors. This study aims to determine preva-
lence of and risk factors for myocardial dysfunction by conventional
echocardiography, strain imaging and cardiac biomarker analyses




We conducted a cross-sectional study within two established
hospital-based cohorts of BC survivors for which we have previously
collected information on cardiovascular disease incidence through
general practitioners and cardiologists.18 Eligible women were treated
for invasive BC (TNM stage I–III) or ductal carcinoma in situ (DCIS)
at ages 40–50 years in the Netherlands Cancer Institute – Antoni van
Leeuwenhoek (NKI-AVL) or University Medical Center Groningen
(UMCG), and were either 5–7 or 10–12 years after initial treatment.
Exclusion criteria were (i) history of radiotherapy or chemotherapy
unrelated to BC/DCIS, (ii) current treatment for BC/DCIS recurrence
or treatment for second malignancy (except non-melanoma skin
cancer and carcinoma in situ of the cervix), (iii) history of cardio-
vascular disease (heart failure, acute coronary syndrome, coronary
revascularization procedure, symptomatic valvular dysfunction, or
cardiomyopathy) before BC/DCIS diagnosis. Patients who had been
treated for a locoregional BC/DCIS recurrence, second BC/DCIS, or
cardiovascular disease after initial BC diagnosis could participate. The
study was approved by the institutional review board of the NKI-AVL
and is registered with ClinicalTrials.gov, identifier NCT02485626.
Study procedures
Eligible women received a written invitation describing the study
objectives and procedures. Non-responders were sent up to two
reminders. Patients who declined participation were diagnosed longer
ago and were treated less often with anthracycline-based chemother-



















































































.. and completed a first study visit (online supplementary Figure S1). Par-
ticipants filled out a baseline questionnaire on current and past lifestyle
factors, physical activity, family history of cardiovascular disease, and
psychosocial functioning. Detailed data on tumour and treatment char-
acteristics, medical history, previous cardiac evaluation, cardiovascular
risk factors and medication use were extracted from medical records,
hospital registries, and obtained through the participants’ general prac-
titioner. When detailed dosing information of chemotherapy was miss-
ing from the medical charts, we assigned standard chemotherapy doses
per administered cycle according to the guidelines per hospital. At
study visit, sociodemographic variables, recent medical history and
current medication use were recorded. Participants underwent stan-
dardized physical examination, blood and urine sampling and elec-
trocardiography (online supplementary Methods S1). NT-proBNP was
measured in serum using an immuno-assay (Cobas platform, Roche
Diagnostics, USA). Transthoracic tissue Doppler echocardiography was
performed according to a standardized acquisition protocol, using the
GE Vivid E9 machine (GE, Horten, Norway) in the UMCG and Philips
iE33 machine (Philips Healthcare, DA Best, The Netherlands) in the
NKI-AVL. Echocardiographic exams were centrally analysed at Gronin-
gen Imaging Core Laboratory by trained observers in accordance with
the American Society of Echocardiography and the European Society of
Cardiology guidelines.19 LVEF was assessed by Simpson biplane method
or, if image quality was insufficient (15.6%), an eyeballing LVEF range
was reported. Other measures of LV function were also quantified
(online supplementary Methods S2). LV GLS was measured using the
Arena two-dimensional cardiac performance analysis (TomTec Imaging
Systems, Unterschleissheim, Germany). Inability to track the LV wall
during the full cardiac cycle precluded GLS measurements in 76 (13%)
patients. GLS was measured twice for a random subset of 102 sub-
jects. Correlation of measurements of the same individual was 0.70
[95% confidence interval (CI) 0.59–0.79].
Statistical analysis
Treatment and follow-up groups were compared using t-tests,
Mann–Whitney tests, and Chi-square tests. No cardiotoxicity equiv-
alence ratio for epirubicin to doxorubicin in BC survivors has been
published. Therefore we used the ratio of the linear regression
coefficient for cumulative epirubicin dose and LVEF and the linear
regression coefficient for cumulative doxorubicin dose and LVEF from
our data to calculate a doxorubicin dose equivalent. Associations
between cumulative doxorubicin dose equivalent (i.e. anthracycline
dose per cycle of 60mg/m2) and LVEF, GLS and NT-proBNP were
evaluated using multivariable linear regression models to assess and
control for potential confounders and test for interactions between
risk factors. We tested variables of interest one by one and a potential
confounder was added to the model if inclusion of this variable
changed the coefficients for the other variables ≥10%. Non-linearity
of the dose–response relationship was evaluated including a quadratic
term for anthracycline dose. Model performance was assessed using
likelihood ratio tests. We performed sensitivity analyses excluding
patients with a locoregional BC recurrence and/or second BC or
clinical cardiovascular disease diagnosed after BC to establish their
influence on outcome measures. For clinical interpretation of the
data, we conducted multivariable logistic regression to study effects of
treatment-related risk factors on myocardial dysfunction prevalence,
defined as a LVEF <54%, according to the range of normal LVEF
values in the general female population,19 GLS>–17%, a cut-off
value indicative of impaired myocardial deformation,20 or NT-proBNP
>125 ng/L.13 Significance tests were two-sided and P< 0.05 was
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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considered statistically significant. Analyses were performed using
Stata/SE (version 13.0; StataCorp LP, College Station, TX, USA).
Results
In total, 569 women were enrolled. Women in the 5–7 year
survivor group had a median follow-up of 6.8 years [interquartile
range (IQR) 6.1–7.5] vs. 11.6 years (IQR 10.9–12.2) in the 10–12
year survivor group. Median age at BC diagnosis was 47.6 years
(IQR 44.9–49.5) in the no-anthracycline group (n = 256) and
46.0 years (IQR 43.1–49.0) in the anthracycline group (n = 313)
(Table 1). Prevalence of hypertension, hypercholesterolaemia, and
diabetes mellitus at BC diagnosis did not differ between patients
treated with and without anthracyclines (Table 1), nor according
to follow-up duration (data not shown). The proportion of cur-
rent and former smokers was lower in the anthracycline group
compared to the no-anthracycline group (current smoker: 24.9%
vs. 28.5%; former smoker: 26.5% vs. 37.9%; P = 0.001) (Table 1).
Treatment characteristics
As expected, anthracycline-treated patients received more exten-
sive treatment, as they more often had triple negative and higher
stage BC (online supplementary Table S1). Thirty-two percent of
anthracycline-treated patients had a mastectomy compared to
5.1% in the no-anthracycline group (P< 0.001) (Table 2). Both
chest wall and internal mammary lymph nodes were more often
irradiated in anthracycline-treated patients (chest wall: 16.6% vs.
2.8%; internal mammary lymph nodes: 11.2% vs. 1.2%; P< 0.001).
In the anthracycline group, 77% of patients received adjuvant
endocrine therapy compared to 28.9% in the no-anthracycline
group (P< 0.001). Most commonly prescribed chemotherapy
regimens were 5-fluorouracil, epirubicin and cyclophosphamide
(FEC) and doxorubicin and cyclophosphamide (AC), followed
by anthracycline-taxane-based combinations (e.g. TAC, FEC-T).
The number of chemotherapy cycles ranged from 1–6. Median
cumulative epirubicin dose was 450mg/m2, median cumulative
doxorubicin dose was 240mg/m2, and median anthracycline dose
was 240mg/m2 (IQR 207–313). Trastuzumab was administered
in 15% of anthracycline-treated patients after completion of the
anthracycline part of their chemotherapy regimen. Patients in
the 5–7 year follow-up group received more extensive surgery
and radiotherapy, higher anthracycline doses and more endocrine
therapy than patients in the 10–12 year follow-up group (online
supplementary Table S2).
Prevalence of risk factors at study visit
Median age at study visit was 55.5 years (IQR 52.7–58.5; online
supplementary Table S3). Overt signs of heart failure (such as
pulmonary congestion and/or peripheral oedema) were absent
at physical examination in all screened patients. Hypertension
and hypercholesterolaemia were the most prevalent cardiovascu-
lar risk factors and their frequency did not differ between treat-
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Total 313 (100) 256 (100)
Age (years) 46.0 [43.1–49.0] 47.6 [44.9–49.5] <0.001
40–45 years 156 (49.8) 90 (35.2)
46–50 years 157 (50.2) 166 (64.8) <0.001
Year of breast cancer
diagnosis
2002–2007 177 (56.6) 140 (54.7)
2008–2012 136 (43.4) 116 (45.3) 0.66
Follow-up time (years) 8.7 [7.1–11.6] 10.3 [6.6–11.5] 0.42
5–7 years 157 (50.2) 120 (46.9)
10–12 years 156 (49.8) 136 (53.1) 0.44
Educational level
Primary education 42 (13.4) 22 (8.6)
Secondary education 65 (20.8) 58 (22.7)
Vocational education 89 (28.4) 62 (24.2)
Higher education 117 (37.4) 114 (44.5) 0.12
Cardiovascular risk factors
Hypertensiona 71 (22.7) 57 (22.3) 0.91
Hypercholesterolaemiab 7 (2.2) 7 (2.7) 0.70
Diabetesb 3 (1.0) 2 (0.8) 0.82
Body mass index
<25 kg/m2 195 (62.3) 174 (68.0)
25–30 kg/m2 82 (26.2) 58 (22.7)
>30 kg/m2 33 (10.5) 20 (7.8)
Unknown 3 (1.0) 4 (1.6) 0.28
Smoking
Never smoked 144 (46.0) 82 (32.0)
Former smoker 83 (26.5) 97 (37.9)
Current smoker 78 (24.9) 73 (28.5)
Unknown 8 (2.6) 4 (1.6) 0.001
Menopausal status
Premenopausal 252 (80.5) 193 (75.4)
Postmenopausal 60 (19.2) 60 (23.4)
Unknown 1 (0.3) 3 (1.2) 0.20
Co-morbidityc
Circulatory diseasec 18 (5.8) 20 (7.8) 0.33
Pulmonary diseased 26 (8.3) 26 (10.2) 0.45
Endocrine, nutritional,
metabolic diseasese




30 (9.6) 23 (8.9) 0.81
Any lipid-lowering drug 4 (1.3) 2 (0.8) 0.56
Any glucose-lowering
drug
3 (1.0) 2 (0.8) 0.82
Any antithrombotic drug 5 (1.6) 2 (0.8) 0.38
Mutation statusg
BRCA1 carrier 11 (3.5) 1 (0.4) 0.01
BRCA2 carrier 9 (2.9) 3 (1.2) 0.16
Other 5 (1.6) 6 (2.3) 0.52
Values are given as n (%), or median [interquartile range].
aHypertension was scored positive if a patient had systolic blood pressure ≥140mmHg,
diastolic blood pressure ≥90mmHg, used antihypertensive drugs (medical record), or if
hypertension was self-reported (patient questionnaire).
bHypercholesterolaemia/diabetes mellitus were scored positive if a patient used
lipid/glucose-lowering drugs (medical record), or if hypercholesterolaemia/diabetes mellitus
was self-reported (patient questionnaire).
cInformation on co-morbidity and medication use was collected from the medical record.
dThis category includes diagnoses I00-I99, excluding I10-I15, International Classification of
Diseases, 10th revision.
eThis category includes diagnoses J00-J99, International Classification of Diseases, 10th
revision.
fThis category includes diagnoses E00-E90, excluding E10-E14 and E78, International Classifi-
cation of Diseases, 10th revision.
gSelf-reported mutation status.
*P-value for difference between treatment groups, calculated with two-sample t-test or
Chi-square test and excluding the unknown category for categorical variables.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Total 313 (100 256 (100
Surgery
Lumpectomy 212 (67.7) 243 (94.9)
Mastectomy 99 (31.6) 13 (5.1)
Othera 2 (0.6) 0 (0) <0.001
Radiotherapy fields
No radiotherapy 23 (7.4) 6 (2.3)
Right breast 107 (34.2) 126 (49.2)
Left breast 96 (30.7) 114 (44.5)
Right chest wall 23 (7.4) 3 (1.2)
Left chest wall 29 (9.2) 4 (1.6)
IMNb 35 (11.2) 3 (1.2) <0.001
Chemotherapy regimenc
FEC 105 (33.6) NA
FAC 17 (5.4) NA
AC 70 (22.4) NA
FEC+T 35 (11.2) NA
AC+T 37 (11.8) NA







≤270mg/m2 31 (21.8) NA
271–450mg/m2 72 (50.7) NA




≤240mg/m2 88 (51.5) NA
241–300mg/m2 58 (33.9) NA




≤180mg/m2 52 (16.6) NA
181–240mg/m2 148 (47.3) NA
241–300mg/m2 88 (28.1) NA
>300mg/m2 25 (8.0) NA
Trastuzumab
No 266 (85.0) 253 (98.8)
Yes 47 (15.0) 3 (1.2) <0.001
Endocrine treatmentg
No 72 (23.0) 182 (71.1)
Tamoxifen only 59 (18.9) 34 (13.3)
Tamoxifen, switch to
aromatase inhibitor
146 (44.7) 26 (10.2)
Aromatase inhibitor only 35 (11.2) 14 (5.5)
Unknown 1 (0.3) 0 (0) <0.001
Values are given as n (%), or median [interquartile range].
A, doxorubicin; C, cyclophosphamide; E, epirubicin; F, 5-fluorouracil; IMN, internal mammary
lymph nodes; NA, not applicable; T, taxane.
aOne patient had an occult breast cancer for which she had an axillary lymph node dissection.
One patient refused surgery.
bEleven patients received IMN irradiation combined with breast irradiation (seven
left-sided/four right-sided) and 27 patients received IMN irradiation combined with chest wall
irradiation (12 left-sided/15 right-sided).
cSixteen percent of anthracycline-treated patients received neo-adjuvant chemotherapy.
dOne patient received four cycles of EC, one patient received six cycles of A+ docetaxel,
one patient received three cycles of AC, followed by three cycles of docetaxel + capecitabin,
one patient received three cycles of AC followed by paclitaxel + carboplatin + trastuzumab,
one patient received four cycles of FEC, followed by two cycles of high dose C+ thiotepa +
carboplatin.
eFor epirubicin a conversion factor of 0.45 was used to calculate a doxorubicin dose equivalent
in relation to cardiotoxicity.
fFor 61% of patients standard chemotherapy doses per administered cycle were assigned
according to the guidelines per hospital.
g In 22% of anthracycline-treated patients and in 35% of no-anthracycline patients, tamox-
ifen/aromatase inhibitor was combined with a gonadotropin-releasing hormone agonist.
*P-value for difference between treatment groups, calculated with Chi-square test and, if




















































































.. mass index at study visit, smoked less and were more often post-
menopausal. Thirteen women (five anthracycline-treated and eight
no-anthracycline patients) had been diagnosed with a cardiovas-
cular disease after BC for which they received treatment (online
supplementary Table S3). Hypertension and hypercholesterolaemia
were more prevalent among 10–12 year survivors than among
5–7 year survivors (online supplementary Table S4).
Markers of myocardial dysfunction
Mean LVEF values were 58.3% [standard deviation (SD) ±4.3%] and
59.9% (SD±4.9%) in the anthracycline- and no-anthracycline group,
respectively. LVEF decreased with increasing cumulative anthracy-
cline dose (LVEF 59.9–0.40% per cycle of 60mg/m2 anthracycline
dose; P< 0.001), with no evidence for non-linearity (Figure 1A;
online supplementary Figure S2). No confounding effects of patient
or treatment variables were identified (Table 3). Other risk factors
that were associated with decreased LVEF were history of car-
diovascular disease (𝛽 = −2.96, P = 0.02), postmenopausal status
(𝛽 = −1.11, P = 0.05) and a known BRCA mutation (𝛽 = −1.94,
P = 0.05; online supplementary Table S5). In a multivariable model,
only a history of cardiovascular disease after BC in addition to
anthracycline dose remained associated with a decreased LVEF
(𝛽 = −3.10, P = 0.02) (Table 3). Interaction analyses showed that
an increasing cumulative anthracycline dose was associated with a
larger decrease in LVEF in patients without hypertension (Table 4).
LVEF <54% was found in 32/312 (10%) of anthracycline-treated
patients compared to 11/255 (4%) of no-anthracycline patients. In
a logistic model, the highest risk of decreased LVEF was seen in
those who received >300mg/m2 anthracycline dose vs. no anthra-
cyclines [odds ratio (OR) 14.98, 95% CI 4.03–55.67, adjusted for
radiotherapy field, endocrine treatment and trastuzumab] (Table 5).
LVEF and GLS were moderately correlated [Pearson correla-
tion coefficient (r) 0.34; online supplementary Figure S3] and this
correlation was stronger in the no-anthracycline group (r = 0.43).
Mean GLS was −17.9% (SD ±2.9%) in the anthracycline group
and−18.8% (SD ±3.2%) in the no-anthracycline group. GLS lin-
early declined with increasing cumulative anthracycline dose in a
model accounting for age at BC diagnosis and radiotherapy field
(GLS = −18.7%+ 0.23% per cycle of 60mg/m2 anthracycline dose;
P< 0.001) (Figure 1B). The association between GLS and anthra-
cycline dose did not change when excluding patients with LVEF
<54%. In the 5–7 year group, the effect of dose on GLS was more
pronounced than in the 10–12 year group (𝛽 = 0.70 vs. 𝛽 = 0.38,
Pinteraction = 0.01) (Table 4). Irradiation of the left breast was asso-
ciated with worse GLS (𝛽 = 0.96, P = 0.002) (Table 3). Impaired
GLS (>−17%) was found in 34% of the anthracycline group and
in 27% of the no-anthracycline group; risk was highest in patients
who received 240–300mg/m2 anthracycline dose (OR 1.83, 95%
CI 1.05–3.17, adjusted for age at BC diagnosis and trastuzumab)
(Table 5). The prevalence of cardiovascular risk factors stratified by
GLS is shown in the online supplementary Table S5.
Median NT-proBNP was 75 ng/L (IQR 50–122) in the anthracy-
cline group and 58 ng/L (IQR 37–92) in the no-anthracycline group.
A linear association between NT-proBNP and cumulative anthra-
cycline dose was found (NT-proBNP 72 ng/L+ 7.2 ng/L per cycle
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Associations between cumulative anthracycline dose
and left ventricular ejection fraction (LVEF) (A), global longitu-
dinal strain (GLS) (B) and N-terminal pro-brain natriuretic pep-
tide (NT-proBNP) (C). Red lines depict linear associations and
grey lines depict 95% confidence intervals (CI). Associations
can be described by LVEF = 59.9–0.40 per cycle of 60mg/m2
anthracycline dose; GLS = -18.7+ 0.23 per cycle of 60mg/m2
anthracycline dose; NT-proBNP = 72+ 7.2 per cycle of 60mg/m2





















































































Table 3 Multivariable linear regression analyses for
left ventricular ejection fraction, global longitudinal




. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
𝜷c P-value 𝜷c P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LVEFd
Anthracycline dose (60mg/m2) −0.41 <0.001 −0.40 <0.001
Age (years)e −0.04 0.50
Diastolic blood pressure (mmHg)f −0.00 0.94
BMI (kg/m2)f 0.05 0.34
Glucose (mmol/L)f −0.26 0.16
Radiotherapy field
Right breast ref.
Left breast −0.50 0.25
Right chest wall −0.85 0.38
Left chest wall 0.10 0.91
IMN −0.83 0.32
No radiotherapy −0.41 0.66
Trastuzumab 0.43 0.54
History of CVD −3.10 0.02
GLS
Anthracycline dose (60mg/m2) 0.21 0.004 0.23 0.001
Age (years) 0.02 0.59 0.06 0.21
Diastolic blood pressure (mmHg) 0.04 0.006
BMI (kg/m2) 0.01 0.77
Glucose (mmol/L) 0.37 0.02
Radiotherapy field
Right breast ref. ref.
Left breast 1.00 0.001 0.96 0.002
Right chest wall 0.05 0.94 −0.06 0.93
Left chest wall −0.24 0.69 −0.26 0.67
IMN 0.06 0.92 0.13 0.83
No radiotherapy −0.06 0.93 −0.18 0.79
Trastuzumab −0.42 0.41
History of CVD 1.72 0.11
NT-proBNP
Anthracycline dose (60mg/m2) 9.4 <0.001 7.2 <0.001
Age (years) 0.5 0.63
Diastolic blood pressure (mmHg) 0.6 0.05
BMI (kg/m2) −1.8 0.02
Glucose (mmol/L) −6.7 0.03
Radiotherapy field
Right breast ref.
Left breast 11.4 0.11
Right chest wall −20.3 0.19
Left chest wall −4.0 0.77
IMN 0.4 0.98
No radiotherapy 4.7 0.75
Trastuzumab −21.0 0.07
History of CVD 104.6 <0.001
BMI, body mass index; CVD, cardiovascular disease; GLS, global longitudinal strain; IMN, inter-
nal mammary lymph nodes; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal
pro-brain natriuretic peptide.
aModel including other potential cardiotoxic treatments and cardiovascular risk factors of
interest. Since systolic and diastolic blood pressure were correlated and stronger associations
between diastolic blood pressure and outcome variables were seen, estimates for diastolic
blood pressure are presented.
bModel including variables that changed the regression coefficient for anthracycline dose (and,
if applicable, other variables) ≥10%.
c𝛽 describes the linear change in LVEF (%), GLS (%), or NT-proBNP (ng/L) per unit increase
of the variable of interest.
dFor 88 patients (15.6%), mean LVEF of an eyeballing LVEF range was used for the analyses.
eAge at breast cancer diagnosis.
fFactor measured at study visit.
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Table 4 Association between left ventricular ejection fraction, global longitudinal strain and N-terminal pro-brain
natriuretic peptide and cumulative anthracycline dose for subgroups
𝜷a LVEF P-valueb 𝜷a GLS P-valueb 𝜷a NT-proBNP P-valueb
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age at BC diagnosis
40–45 years −0.61 0.14 1.1
46–50 years −0.48 0.49 0.20 0.66 5.2 0.18
Follow-up time
5–7 years −0.81 0.70 11.5
10–12 years −0.54 0.13 0.38 0.01 8.7 0.35
Trastuzumab
No −0.41 0.26 7.7
Yes −0.73 0.53 −0.06 0.41 11.0 0.69
Hypertension at BC diagnosis
No −0.50 0.26 7.5
Yes −0.06 0.04 0.07 0.22 6.3 0.73
Hypertension at study visit
No −0.59 0.26 7.7
Yes −0.06 <0.01 0.16 0.44 6.2 0.64
BC, breast cancer; GLS, global longitudinal strain; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide.
a𝛽 describes the linear change in LVEF (%), GLS (%), or NT-proBNP (ng/L) per anthracycline cycle (60mg/m2).
bPinteraction.
Table 5 Multivariable logistic regression analyses of decreased left ventricular ejection fraction, impaired global
longitudinal strain and elevated N-terminal pro-brain natriuretic peptide by treatment




. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
n/Na OR 95% CI n/Nb OR 95% CI n/Nc OR 95% CI n/Nd OR 95% CI
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Model 1
No anthracyclines 11/255 1.00 ref. 60/226 1.00 ref. 31/256 1.00 ref. 76/226 1.00 ref.
Anthracyclines 32/312 2.54 1.25–5.14 91/267 1.43 0.97–2.11 71/313 2.13 1.35–3.37 138/267 2.11 1.46–3.04
Model 2e
Chemotherapy
No anthracyclines 11/255 1.00 ref. 60/226 1.00 ref. 31/256 1.00 ref. 76/226 1.00 ref.
≤180mg/m2 4/52 3.66 0.99–13.71 13/41 1.38 0.66–2.85 4/52 0.66 0.22–1.95 18/40 1.60 0.81–3.17
181–240mg/m2 12/148 2.83 1.11–7.22 41/125 1.53 0.93–2.52 34/148 2.35 1.36–4.08 61/125 1.98 1.25–3.15
241–300mg/m2 10/88 4.05 1.54–10.66 30/79 1.83 1.05–3.17 27/88 3.30 1.83–5.96 49/79 3.27 1.92–5.58
>300mg/m2 6/24 14.98 4.03–55.67 7/22 1.45 0.56–3.78 6/25 2.41 0.89–6.53 10/22 1.68 0.69–4.07
Trastuzumab
No 40/518 1.00 ref. 141/453 1.00 ref. 95/519 1.00 ref. 197/453 1.00 ref.
Yes 3/49 0.67 0.19–2.37 10/40 0.68 0.32–1.49 7/50 0.59 0.25–1.39 17/40 0.75 0.38–1.49
CI, confidence interval; GLS, global longitudinal strain; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide; OR, odds ratio.
aPatients included in the analyses: n = 567. For two patients, LVEF could not be measured.
bPatients included in the analyses: n = 493. For 76 patients, GLS could not be measured.
cPatients included in the analyses: n = 569.
dPatients included in the analyses: n = 493.
eORs for LVEF <54% were calculated in a multivariable model including radiotherapy field and endocrine treatment in addition to trastuzumab. ORs for GLS>–17% were
calculated in a multivariable model including age at breast cancer diagnosis in addition to trastuzumab.
of 60mg/m2 anthracycline dose; P< 0.001) (Table 3, Figure 1C);
risk of NT-proBNP >125 ng/L was 2.13-fold increased (95% CI
1.35–3.37) in patients who received anthracyclines (71/313; 23%)
compared to no anthracyclines (31/256; 12%) (Table 5). When







. similar results for the risk of having ≥1 abnormal marker increasing
with anthracycline dose (P-trend <0.001) (Table 5).
Sensitivity analyses excluding (i) patients with a recurrence
and/or second BC/DCIS (n = 32), (ii) patients who developed
cardiovascular disease during follow-up, and (iii) patients who used
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angiotensin-converting enzyme inhibitors, did not change results
for any of the outcome parameters (data not shown).
Discussion
This study represents one of the largest comprehensive assess-
ments of cardiac function by echocardiography, strain imaging and
biomarker analysis in young, long-term BC survivors. Other stud-
ies in this research area were smaller, included older BC patients
and reported results on fewer outcomes.21,22 A substantial pro-
portion of survivors in our cohort presented with myocardial
dysfunction; in the anthracycline group, LVEF <54%, GLS>–17%
and NT-proBNP >125 ng/L were observed in 10%, 34%, and 23%
of patients, respectively. More than half of anthracycline-treated
women (54%) had at least one indicator of myocardial dysfunction.
The observed linear relationship between cumulative anthracy-
cline dose and LVEF is consistent with previous findings,2 indicating
that there is no safe anthracycline dose below which there is no
increased risk of cardiac damage. A novel result is the observed
linear association between anthracycline dose and GLS. Further-
more, patients who received left breast irradiation had significant
worse GLS values.
Prior large epidemiological studies have provided much infor-
mation on risk of cardiac disease after BC treatment, but lacked
data from an in-depth cardiac assessment that includes evaluation
of early cardiotoxicity.23,24 The use of registry data in such studies
increases misclassification of exposure and event status compared
to our study.23 Qin et al.24 abstracted cardiac imaging information
from medical records, which may have led to higher risk estimates,
since outcome data were likely only available for patients with signs
and/or symptoms of cardiac disease.
Caram et al.25 did evaluate the prevalence of cardiac dysfunction
by a biomarker assay and an echocardiogram. They found that LVEF
<55% was present in 11.5% of doxorubicin-treated BC survivors
(median age: 56 years, median follow-up: 6 years) with an elevated
cardiac biomarker at first screening (71% of included patients).
Another Dutch study (n = 350, median follow-up: 10 years) found
a LVEF <54% in 15.3% of patients, possibly due to the higher preva-
lence of cardiovascular risk factors. Almost 38% of participants
were prescribed cardiovascular medication at study visit,22 com-
pared to 19.7% in our study. Interestingly, these previous studies
showed no clear effect of cumulative anthracycline dose and may
be the result of lower patient numbers and limited dose ranges.
Somewhat surprisingly, we observed no association between
trastuzumab and either LVEF, GLS or NT-proBNP. Trastuzumab is
known to increase the risk of LVEF decline, but this decline is often
reversible.26 Long-term cardiotoxicity data of trastuzumab-treated
patients in a population-based setting are, however, limited.27 In this
cohort, the prevalence of LVEF <54% among trastuzumab-treated
patients was only 6% (Table 5), suggesting that the cardiotoxic effect
of trastuzumab may indeed be transient, but strong conclusions
about the combined effects of anthracyclines and trastuzumab
cannot be drawn from our data, since only 47 patients received
both agents.
We found that about a third of screened patients had impaired



















































































.. was −23.3% (±3.1%) in females aged 40–60 years,20 compared
to mean GLS in our total cohort of −18.3% (±3.1%): −17.9%
(±2.9%) in anthracycline-treated patients and−18.8% (±3.2%) in
the no-anthracycline group. It should be noted that part of this
∼5% difference may be explained by differences in the prevalence
of cardiovascular risk factors associated with worse GLS. Since
previous studies have shown that GLS is a promising predictor for
subsequent cardiotoxicity in BC patients,12,28 we expect some of
the women with impaired GLS to develop clinical cardiotoxicity.
In addition, we showed that GLS may not only detect
anthracycline-related cardiotoxicity, but also radiotherapy-related
cardiac injury, as left-sided breast irradiation was associated with
worse GLS in a model including anthracycline dose (𝛽 = 0.96,
P = 0.002). We believe that this finding does not reflect the use
of older radiation techniques that expose the heart to higher
radiation doses, as stratification by follow-up period yielded sim-
ilar results. Although efforts have been made to reduce cardiac
radiation exposure, the heart may still be exposed to ∼4 Gy
when left-sided radiotherapy is given. Only a few small studies
have investigated the potential of strain imaging as a screening
tool for radiotherapy-related cardiotoxicity and showed promising
results.29,30 Patients in these studies were assessed, however,
<6weeks after radiotherapy and did not receive chemotherapy.
Data on the long-term combined effects of anthracyclines and
radiotherapy on GLS are limited and this finding requires further
investigation.
Remarkably, the effect of anthracycline dose on GLS was more
pronounced in patients diagnosed more recently. Similar trends
were seen for LVEF and NT-proBNP (Table 4). Patients diagnosed
5–7 years ago more often received chest wall irradiation, adjuvant
endocrine therapy and taxanes in addition to anthracycline-based
chemotherapy. Inclusion of these treatment factors to our sta-
tistical model, however, did not change the relationship between
anthracycline dose and GLS in the two follow-up groups. Although
we tried to eliminate the influence of other (cardiovascular) risk
factors on GLS, residual confounding cannot be ruled out. Con-
firmation of this result is therefore necessary and will be possible
when prospective measurements for this cohort become available.
We also observed a linear association for anthracycline dose
and NT-proBNP. Furthermore, 23% of patients in the anthracycline
group had NT-proBNP >125 ng/L vs. 12% in the no-anthracycline
group. Sandri et al.16 showed that early, persistent increases in
NT-proBNP may predict subsequent clinical cardiotoxicity. Also,
in the European Society of Cardiology position paper it was
reported that abnormal NT-proBNP is indicative of an increased
risk of cardiotoxicity among patients treated with anthracyclines.4
Evidence-based strategies to prevent progression to overt cardiac
disease in this particular patient group should be further investi-
gated. We were unable to identify patients with LVEF <54% using
NT-proBNP >125 ng/L (online supplementary Figure S2) and the
question remains whether the cut-off value for ruling out heart
failure in the general population13 is appropriate for detecting car-
diotoxicity in BC survivors.
When interpreting our results, some limitations of our study
should be considered. Included patients had no cardiovascular
assessment at BC diagnosis and we were therefore unable to
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investigate changes in outcome measures from baseline. However,
we believe that the influence of subclinical cardiovascular disease at
BC diagnosis was minimal, since we studied BC patients diagnosed
at age 40–50 years, who had a low prevalence of cardiovascular risk
factors. Second, inability to track the LV wall during the full cardiac
cycle precluded GLS measurements in 13% of screened patients.
We explored patient and treatment characteristics of women
for whom GLS was not available. They received more extensive
treatment in terms of anthracycline dose and radiotherapy fields
compared to patients with GLS measurement (data not shown)
and this could have led to an underestimation of the association
reported. Finally, our study was cross-sectional and patients who
developed cardiovascular disease prior to study invitation might
have been over- or under-represented. However, the study was
embedded within established BC cohorts and for the NKI-AVL
cohort we have information on cardiovascular disease incidence
and mortality,18 enabling us to explore selection bias. We found no
evidence for patient selection by comparing cardiovascular disease
incidence rates of responders and non-responders, and since only
seven patients died of cardiovascular disease before study initiation,
we believe that survival bias is negligible.
Several task forces have made great efforts to set up guidelines
for prevention and monitoring of cardiotoxicity among (breast)
cancer survivors.3–5 However, these guidelines are not broadly
used in clinical practice, since the quality of evidence supporting
those guidelines is still insufficient. We believe that results of the
current analyses do not yet allow us to recommend a specific
strategy for monitoring BC survivors, since follow-up data are
crucial and are expected to contribute to knowledge about the
course of cardiac (dys)function over time, identification of patients
at high risk of developing overt cardiac disease, and adaptation
of new methods for early detection of cardiotoxicity in cancer
survivors.
In conclusion, we found that 5–12 years after treatment with
anthracycline-based chemotherapy, a substantial proportion of
young BC survivors showed signs of myocardial dysfunction based
on GLS measurements and NT-proBNP levels, whereas the num-
ber of women with a decreased LVEF was much smaller. Longi-
tudinal assessment is essential to determine the prognostic value
of strain and cardiac biomarkers in the development of overt car-
diotoxicity and identify high-risk BC survivors who may benefit
from cardiac surveillance.
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.. Table S4. Prevalence of (cardiovascular) risk factors at study visit
by follow-up group.
Table S5. Prevalence of (cardiovascular) risk factors at study visit
by global longitudinal strain.
Figure S2. Associations between cumulative anthracycline dose
and left ventricular ejection fraction (LVEF) (A), global longitudinal
strain (GLS) (B) and N-terminal pro-brain natriuretic peptide
(NT-proBNP) (C).
Figure S3. (A) Scatter plot of left ventricular ejection fraction
(LVEF) (%) and global longitudinal strain (GLS) (%) and linear regres-
sion line. (B) Scatter plot of LVEF (%) and N-terminal pro-brain
natriuretic peptide (NT-proBNP) (ng/L) and linear regression line.
(C) Scatter plot of GLS (%) and NT-proBNP (ng/L) and linear
regression line.
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